A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Clinical trial NCT03847649 · RECRUITING
Trial details
- NCT number
- NCT03847649
- Sponsor
- Canadian Cancer Trials Group
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-09
- Primary completion
- 2030-04-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.